semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Graves' Disease Key Male and female patients 18 to 65 years of age included Women of child-bearing potential must be willing to use highly effective methods of contraception during the study treatment epoch and for 12 weeks after the last study treatment Graves' hyperthyroidism, with the following labs measured at screening TSH<LLN and either FT3>ULN or FT4> ULN and TRAb ≥ 2.5 IU/L Patients must weigh at least 40 kg to participate in the study Key  History of treatment of Graves' disease with radio-iodine ablation or thyroidectomy and/or current treatment with anti-thyroid drugs (methimazole or propylthiouracil) within one week of starting the study treatment History of hyperthyroidism not caused by Graves' disease (e.g. toxic multinodular goiter, autonomous thyroid nodule, or acute inflammatory thyroiditis) and/or history or presence of thyroid storm (fever, profuse sweating, vomiting, diarrhea, delirium, severe weakness, seizures, markedly irregular heartbeat, yellow skin and eyes (jaundice), severe low blood pressure, and coma) Previous treatment with a B cell-depleting biologic agent or any other immune-modulatory biologic agent within 5 half-lives (experimental or approved) History of recurrent clinically significant infection or of recurrent bacterial infections with encapsulated organisms History of primary or secondary immunodeficiency, including a positive HIV (ELISA and Western blot) test result History or evidence of tuberculosis by either of the following tests Positive PPD skin test (size of induration measured after 48-72 hours, and a positive result is defined as an induration of ≥ 5mm or according to local practice/guidelines) OR Positive QuantiFERON TB-Gold test Plans for immunization with a live vaccine within a 2-month period before enrollment or during the study period Treatment with immunomodulatory drugs, such as cyclosporine A, methotrexate, and/or cyclophosphamide within 3 months from baseline. Glucocorticosteroid therapy with prednisolone up to 10 mg daily is permitted if patients are on stable dose for more than 3 months before enrollment in the study
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 5.0-18.0,  Thyroiditis Hashimoto For patients Subjects 5 to 18 years old First diagnosis of hypothyroidism due to Hashimoto's thyroiditis (high levels of serum antithyroid autoantibodies (antiTPO, anti-TgAb). For Controls Healthy individuals 5 to 18 years old BMI for age between 15th and 85th percentile (z-score between -1 and +1)  For patients Presence of euthyroidsm, subclinical hypothyroidism, hyperthyroidism Pre-existing medical treatment for clinical hypothyroidism Taking other medications (eg growth hormone, corticosteroids) in the last 3 months Taking food supplements (eg omega-3 fatty acids, amino acids) in the last 3 months Concomitant endocrine, metabolic, degenerative and / or chronic diseases other than obesity (eg diabetes, hyper / hypo-cortisolemia, cardiovascular diseases, kidney diseases, myasthenia, neurological diseases, psychiatric disorders eg anorexia nervosa, cancer, anemia, celiac disease, chromosomal abnormalities eg syndrome Turner, Down, etc) Participation in any daily organized physical activity (sport), more than 1 hour per day Presence of menstrual disorders in adolescent girls Having any kind of nutrition/dietary intervention (eg weight loss diet, hypocaloric, ketogenic, low-protein diet), in the last 6 months. For Controls Presence of any form of thyroid disease
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 1.0-999.0,  Macrophage Activation Syndrome Criteria:1] Previous diagnosis of systemic juvenile idiopathic arthritis (sJIA) and fulfills the Ravelli (4) for macrophage activation syndrome with either: two or more Laboratory 1. Decreased platelet count (≤262 ×10 9/L) 2. Elevated levels of aspartate aminotransferase (>59 U/L) 3. Decreased white blood cell count (≤4.0 × 109/L) 4. Hypofibrinogenemia (≤2.5 g/L) or, three or more combined clinical/laboratory 1. Decreased platelet count (≤262 × 109/L) 2. Elevated levels of aspartate aminotransferase (>59 U/L) 3. Decreased white blood cell count (≤4.0 × 109/L) 4. Hypofibrinogenemia (≤2.5 g/L) 5. Central nervous system dysfunction (irritability, disorientation, lethargy, seizures, coma) 6. Hemorrhages (purpura, easy bruising, mucosal bleeding) 7. Hepatomegaly (≥3 cm below the costal margin or confirmed by imaging) OR 2] No previous diagnosis of sJIA and serum ferritin > 2,000 ng/ml and 3 out of the following: 1. Bicytopenia with two of the following: 1. Absolute Neutrophil Count < 1,000, 2. Platelets < 100, 000/mm3, 3. Hemoglobin < 9 mg/dl 2. Fasting triglyceride >265 mg/dL 3. Splenomegaly 4. ALT OR AST > 120 IU/L (or > 2x upper limit of normal) 5. Fever with temp ≥ 101° F 6. Fibrinogen < 1.5 g/L (150 mg/dl) or INR > 1.5 or d-dimer > 500 ng/ml -  Evidence of malignancy 2. Culture evidence of systemic bacterial infection at the time of screening 3. Known EBV viremia by PCR at time of screening (positive serologies are not an exclusion; results of EBV testing will not be necessary for enrollment, but may be ordered as part of the standard of care assessment to guide future management as results become available) 4. Previous treatment for the current MAS episode with corticosteroids, anakinra, tocilizumab, anti-TNF therapy or cyclosporine 5. <1 year of age 6. Family history of familial HLH 7. Evidence of any of the following 1. Creatinine at the time of screening > 2X ULN or > twofold increase from patient's baseline creatinine within past 3 months (if known) 2. Albumin < 1.5 at the time of screening 3. Mechanical ventilation at the time of screening 4. Hypotension requiring use of pressors at the time of screening
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Graves Disease Graves' disease :patients treated for Graves' disease, the diagnosis date less than 4 months Control : patients cared for nodules or goiter  Patients undergoing immunosuppressive therapy including corticosteroids
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Men or women aged ≥ 18 years Diagnosed with acromegaly Receiving treatment with ATG 120 mg at extended dosing intervals (> 4 weeks) for at least six months before the study visit Assay data (blood GH and IGF-1 levels) from immediately before the study visit (performed at least six months after starting the treatment) is available Able to sign the informed consent form for study participation  Received radiation therapy treatment in the last six months Active participation in another clinical study Physical or mental disorders that, in the investigator's opinion, could affect their ability to sign the informed consent form Pregnancy or breastfeeding for female patients No data in their medical records on the treatment start date for ATG 120 mg at extended dosing intervals or on changes to the schedule of administration over the last six months
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Patients With Adnexal Mass Prior to Surgery Any woman presenting with an adnexal mass judged not to be physiological and likely to undergo surgery (primarily planned for surgical management based on subjective assessment by the ultrasound examiner; however, the ultrasound examiner is allowed to change the advised management to conservative management after the results of Simple Rules or ADNEX are known) Pregnant patients can be included but will be analysed separately Patients finally selected for conservative management can be included but will not be used for all statistical analyses For patients selected for surgery, delay of surgery is not an criterion for this study, but for selected objectives only those patients in whom surgery was performed within 180 days after the ultrasound examination will be assessed Patients can be selected at any age, but for patients <18 years old, a guardian's permission should be obtained Patients that only underwent transabdominal scanning can be included in the study, but will be analysed separately  Previous bilateral adnexectomy Denial or withdrawal of informed consent
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 1.0-31.0,  B Acute Lymphoblastic Leukemia Central Nervous System Leukemia Ph-Like Acute Lymphoblastic Leukemia Testicular Leukemia Patients must be enrolled on APEC14B1 and consented to Screening on the Part A consent form prior to enrollment on AALL1131 White Blood Cell Count (WBC) Age 1-9.99 years: WBC >= 50 000/uL Age 10-30.99 years: Any WBC Age 1-30.99 years: Any WBC with Testicular leukemia CNS leukemia (CNS3) Steroid pretreatment Patients must have newly diagnosed B lymphoblastic leukemia (2008 World Health Organization [WHO] classification) (also termed B-precursor acute lymphoblastic leukemia); patients with Down syndrome are also eligible Organ function requirements for patients with Ph-like ALL and a predicted TKI-sensitive mutation: patients identified as Ph-like with a TKI-sensitive kinase mutation must have assessment of organ function performed within 3 days of study entry onto the dasatinib arm of AALL1131  With the exception of steroid pretreatment or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or any cancer diagnosed prior to the initiation of protocol therapy on AALL1131; patients cannot have secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy; patients receiving prior steroid therapy may be eligible for AALL1131 Patients with BCR-ABL1 fusion are not eligible for post-induction therapy on this study but may be eligible to enroll in a successor Children's Oncology Group (COG) Philadelphia positive (Ph+) ALL trial by day 15 Induction DS HR B-ALL patients with Induction failure or BCR-ABL1 Female patients who are pregnant are ineligible since fetal toxicities and teratogenic effects have been noted for several of the study drugs Lactating females are not eligible unless they have agreed not to breastfeed their infant Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  THYROTOXICOSIS Subjects visits outpatient department due to a suspicion of thyroid disease  Psychological disorders, severe inflammatory or infection diseases
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Neoplasm, Trophoblastic Gestational Trophoblastic Disease Hydatidiform Mole Hydatidiform Mole, Invasive Patients are eligible if they have a histologically proven trophoblastic disease, or a diagnosis of gestational trophoblastic neoplasia done on an abnormal evolution of hCG  none
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.247,  Bottlefeeding Infant, Premature, Diseases birth weight <= 1500 gr gr 2. gestational age <= 32 weeks 3. postnatal age at randomization: between 7 days  congenital anomaly multi organ failure sepsis surgical pathology inherited metabolic diseases exclusively formula feeding
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 3.0-18.0,  Hypothyroidism Children with primary acquired hypothyroidism that require Levothyroxine therapy (naïve patients, < 18 years) Informed consent from parents and patient  Age < 3 years Patients with secondary hypothyroidism, euthyroid sick syndrome or thyroid hormone resistant Patients with celiac disease, type I diabetes or other known autoimmune diseases Patients with genetic diseases or syndromes, such as Down, Williams-Beuren, Turner Assumption of antibiotics, probiotics, prebiotics, or other medications that could affect the gut microbiota in the month before the beginning of the study Gastrointestinal infectious diseases in the month before the beginning of the study Hypersensitivity to levothyroxine or any of the ingredients contained in the two pharmaceutical formulations Untreated adrenal insufficiency, untreated pituitary insufficiency and untreated thyrotoxicosis Patients with cardiovascular disease Patients who show with impaired pancreatic function measured using the assay in faecal fat (steatocrit) at the screening visit
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pregnancy Protein-Energy Malnutrition Anemia First trimester of pregnancy Anemic or Mid Upper Arm Circumference < 23.5cm or no weight gain Plan to deliver at village midwives residence in the study area  severe anemia < 7.0g/dl
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Obesity Pre-pregnancy body mass index of at least 30 kg/m2 (per patient report of weight) Less than 16 weeks gestation Gestational weight gain (GWG) less than < 11 pounds from their pre-pregnancy weight to time of potential study enrollment Singleton gestation Access to a phone  BMI less than 30 kg/m2 Gestational age greater than or equal to 16 weeks Active diagnosis of cancer on their electronic health record problem list Acquired immunodeficiency syndrome (AIDS) Palliative medicine patients Multiple gestations GWG in excess of 11 pounds prior to study enrollment Patients with Non-Geisinger prenatal care providers Vegan diet Malabsorptive conditions
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Valvular Heart Disease Stenosis and Regurgitation (Diagnosis) Presence of aortic stenosis, mitral or aortic regurgitation at the time of an echocardiography at the "Cliniques Universitaires Saint Luc"
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Gestational Diabetes Pregnant women <16 years of age High risk for GDM (at least 1 of the risk factors) BMI >30 Previous GDM First degree relatives with GDM Previous unexplained still birth Previous baby >4.5kg PCOS Ethnic minority groups Age >35years  Pregestational Type 1 or Type 2 Diabetes Diagnosis of B12 or folate deficiency in the current pregnancy Previous pregnancies with NTDs Diagnosis of severe aneamia (<10g/dL) Vitamin B12 injections in the previous 6 months
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Thyroid Obesity Insulin Resistance Autoimmune Thyroiditis Obesity (BMI > 40 kg/m2) 2. Age: 18-65  Diagnosis of obesity secondary to primary endocrine or systemic disease (e.g. Cushing's syndrome) 2. Evidence of clinically relevant thyroid disease 3. Chronic systematic inflammatory disease (e.g. rheumatoid arthritis) 4. Pregnancy 5. Treatment with anti-inflammatory drugs (e.g. corticosteroids) 6. Type 1 diabetes mellitus
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 4.0-999.0,  Medication Adherence Cystic Fibrosis Patients with diagnosis of Cystic fibrosis at all ages Their associated CF Center professionals Their associated family CF patients that should be treated with one or more of these chronic medications: Tobi (Tobramycin), (Colistin), Pulmozyme (Dornase Alpha), Hypertonic Saline (HS), Creon (pancreatic enzymes), AquaADEKs (Multivitamin) Patients willing to participate in a trial Presence of a parent/guardian capable of providing informed consent; and Patients attending CF clinic at least once every 12 months  Absence of a parent/guardian or unwillingness to provide permission Potential participant declines to provide assent; and Transplant patients